Ali Rizvi Selected Research

Stents

12/2013	Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.
9/2013	Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
5/2012	Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting stent implantation: pooled analysis from the SPIRIT III and SPIRIT IV clinical trials.
6/2011	Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
12/2010	Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
5/2010	Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ali Rizvi Research Topics

Disease

6	Thrombosis (Thrombus) 12/2013 - 05/2010
5	Myocardial Infarction 09/2013 - 05/2010
3	Death (Near-Death Experience) 09/2013 - 05/2010
3	Ischemia 09/2013 - 05/2010
2	Neoplasms (Cancer) 11/2023 - 01/2022
2	Coronary Artery Disease (Coronary Atherosclerosis) 09/2013 - 05/2010
2	Cardiovascular Diseases (Cardiovascular Disease) 09/2013 - 05/2012
1	COVID-19 12/2023
1	Medulloblastoma 11/2023
1	Immunoglobulin Light-chain Amyloidosis 07/2022
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022
1	Adenocarcinoma 01/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Hypercholesterolemia 01/2015
1	Dyslipidemias (Dyslipidemia) 01/2015
1	Atherosclerosis 01/2015
1	Diabetes Mellitus 12/2010
1	Type 2 Diabetes Mellitus (MODY) 01/2009
1	Myocardial Stunning (Stunned Myocardium) 01/2002

Drug/Important Bio-Agent (IBA)

2	Everolimus FDA Link 09/2013 - 05/2010
2	Paclitaxel (Taxol)FDA LinkGeneric 09/2013 - 05/2010
1	Histones (Histone)IBA 11/2023
1	Lysine (L-Lysine)FDA Link 11/2023
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 11/2023
1	MethyltransferasesIBA 11/2023
1	Congo RedIBA 07/2022
1	Coloring Agents (Dyes)IBA 07/2022
1	Gemcitabine FDA Link 01/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	dubermatinibIBA 01/2022
1	oxidized low density lipoproteinIBA 01/2015
1	LDL CholesterolIBA 01/2015
1	LipidsIBA 01/2015
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2015
1	Lipoproteins (Lipoprotein)IBA 01/2015
1	omega-Chloroacetophenone (Mace)IBA 05/2012
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2009
1	Oxidants (Oxidizing Agents)IBA 01/2002

Therapy/Procedure

6	Stents 12/2013 - 05/2010
2	Percutaneous Coronary Intervention 06/2011 - 12/2010
1	Palliative Care (Palliative Therapy) 12/2023
1	Therapeutics 01/2022
1	Drug-Eluting Stents 12/2010